2-(1H-1,2,3-三唑-1-基)嘧啶 | 30597-96-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-(1H-1,2,3-三唑-1-基)嘧啶
• 英文名称: 2-[1,2,3]triazol-1-yl-pyrimidine
• 英文别名: 2-(1H-1,2,3-Triazol-1-yl)pyrimidine；2-(triazol-1-yl)pyrimidine
• CAS: 30597-96-7
• 化学式: C₆H₅N₅
• mdl: MFCD18967873
• 分子量: 147.139
• InChiKey: JMPSZSWPTOULLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  嘧啶 N-氧化物 、 1-(p-tolylsulfonyl)triazole 在 N,N-二异丙基乙胺 作用下， 反应 6.5h， 以65%的产率得到2-(1H-1,2,3-三唑-1-基)嘧啶
  参考文献：
  名称：

  One-Step Conversion of Azine N-Oxides to α-1,2,4-Triazolo-, 1,2,3-Triazolo, Imidazolo-, and Pyrazoloheteroarenes

  摘要：

  Pyridine, quinoline, isoquinoline, azaindole, and pyrimidine N-oxides were converted to their alpha-triazole and alpha-diazole derivatives by treatment with the corresponding p-toluenesulfonylazoles and Hunig's base at elevated temperatures.

  DOI：

  10.1021/jo1001017

文献信息

• [EN] DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY<br/>[FR] ANTAGONISTES DU RÉCEPTEUR D3 DE LA DOPAMINE AYANT UN FRAGMENT BICYCLO
  申请人：INDIVIOR UK LTD

  公开号：WO2017021920A1

  公开（公告）日：2017-02-09

  The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

  该披露提供了具有化学式（I）的化合物，其中取代基如本文所定义。这些化合物可用于调节多巴胺D3受体，并用于治疗与之相关的疾病，如成瘾、药物依赖和精神疾病。
• [EN] TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLYL PYRIMIDINONE EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016145614A1

  公开（公告）日：2016-09-22

  The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式I的嘧啶甲酰胺化合物，该化合物作为治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统障碍的治疗剂是有用的。本发明还涉及使用这些化合物来治疗神经和精神障碍，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
• [EN] AZOLO TRIAZINES AND PYRIMIDINES<br/>[FR] AZOLO TRIAZINES ET PYRIMIDINES
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1999038868A1

  公开（公告）日：1999-08-05

  (DE) Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathalogical disturbance and stress.(EN) Corticotropin releasing factor (CRF) antagonists of formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.(FR) L'invention concerne des antagonistes de facteur de libération de corticotrophine (CRF) de la formule (I) ou (II) et leur utilisation dans le traitement de l'anxiété, de la dépression et d'autres troubles psychiatriques et neurologiques, ainsi que le traitement d'affections immunologiques, cardiovasculaires ou liées au coeur et de l'hypersensibilité du côlon associée à des troubles psychopathologiques et au stress.

  (DE) Corticotropin-Releasing-Faktor (CRF)-Antagonisten der Formel I oder II und ihre Verwendung zur Behandlung von Angstzuständen, Depressionen und anderen psychiatrischen, neurologischen Störungen sowie zur Behandlung von immunologischen, kardiovaskulären oder herzbezogenen Erkrankungen und kolonischen Hypersensitivitäten, die mit psychopathologischen Störungen und Stress verbunden sind. (EN) Corticotropin releasing factor (CRF) antagonists of formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress. (FR) Les antagonistes du facteur de libération de la corticotrophine (CRF) de formule (I) ou (II) et leur utilisation dans le traitement de l'anxiété, de la dépression et d'autres troubles psychiatriques et neurologiques, ainsi que dans le traitement de maladies immunologiques, cardiovasculaires ou liées au cœur et de l'hypersensibilité colique associée à des troubles psychopathologiques et au stress.
• Triazolyl pyrimidinone compounds as PDE2 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10358435B2

  公开（公告）日：2019-07-23

  The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式 I 的嘧啶羧酰胺化合物，该化合物可作为治疗剂用于治疗与磷酸二酯酶 2 (PDE2)相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能低下或基底节功能障碍相关的疾病。
• AZOLO TRIAZINES AND PYRIMIDINES
  申请人：Du Pont Pharmaceuticals Company

  公开号：EP1049699A1

  公开（公告）日：2000-11-08